Can You Take HRT After Cancer? What You Need to Know After Breast and Other Cancers

Highlights: HRT after breast cancer and other cancers

  • It depends on your cancer.
    HRT is generally not recommended for breast cancer survivors but can be discussed after many other cancers.
  • Vaginal oestrogen is different.
    Your breast team may agree to it if moisturisers fail, with extra care on an aromatase inhibitor.
  • Non-hormonal treatments can help.
    CBT and several medicines eased hot flushes in trials.
  • Early menopause needs care.
    Unless you had breast or hormone-sensitive cancer, HRT until about 51, agreed with your oncologist, helps protect your bones and heart.
If you are facing menopause after breast cancer or another cancer, you may have been told HRT is off the table. That is hard when hot flushes, poor sleep or vaginal dryness wear you down. There is more help than you may think.

Quick Answer: It depends on the type of cancer you had

Systemic HRT after breast cancer (tablets, patches or gels) is generally not recommended. Non-hormonal treatments come first, and vaginal oestrogen may be considered, with extra care on an aromatase inhibitor. After many other cancers, including cervical and early, low-risk womb cancer, HRT is often possible. You decide with your oncologist or breast team and a menopause specialist.

Can you take HRT after breast cancer?

Usually not, but other treatments can help. Menopausal HRT differs from hormone therapy for breast cancer, such as tamoxifen. NICE NG101 says to stop systemic HRT at diagnosis and offer it afterwards only in exceptional cases of severe symptoms, after discussing the risks. In the UK this is off-label for all HRT, and the British Menopause Society (BMS) says any use needs your breast team’s input and must not be combined with an aromatase inhibitor.

All three randomised trials of HRT or tibolone (an HRT-like medicine) after breast cancer stopped early, two because of more recurrences. In HABITS, after a median of 4 years, 39 of 221 women on HRT had breast cancer again, compared with 17 of 221 without it. In LIBERATE, recurrence was 15.2% on tibolone and 10.7% on placebo. The Stockholm trial found no clear overall rise, but more cancers in the other breast.

What the main trials of HRT after breast cancer found

Three randomised trials compared women who took HRT or tibolone (an HRT-like medicine) after breast cancer with women who did not.

HRT or tibolone

No HRT or placebo

HRT, mostly oestradiol with norethisterone 221 women in each group median 4 years
Women who had breast cancer again
With HRT: 39 of 221
Without HRT: 17 of 221
More new breast cancer events with HRT.
Hazard ratio 2.4 (95% CI 1.3 to 4.2)
Deaths from breast cancer: 6 with HRT and 5 without, not a significant difference.
Holmberg et al., JNCI 2008
Stockholm
HRT with progestogen kept to a minimum 378 women 10.8 years of follow-up
New breast cancer events
With HRT: 60 events
Without HRT: 48 events
No clear overall difference.
Hazard ratio 1.3 (95% CI 0.9 to 1.9)
Cancers in the other breast: 14 with HRT and 4 without. No difference in deaths.
Fahlen et al., Eur J Cancer 2013
Tibolone 3,098 women median 3.1 years
Women who had breast cancer again
With tibolone: 15.2% (237 of 1,556)
Placebo: 10.7% (165 of 1,542)
More recurrences with tibolone.
Hazard ratio 1.40 (95% CI 1.14 to 1.70)
The authors concluded that tibolone increases the risk of recurrence.
Kenemans et al., Lancet Oncol 2009
All three trials were stopped early, two because of more recurrences.
Each trial has its own scale: the bars compare the two groups within a trial, not one trial with another. Hazard ratio: above 1 means more events with HRT or tibolone. When the range (95% CI) includes 1, the difference could be down to chance.
Your own risk depends on your cancer and your treatment. Please talk it through with your breast team and a menopause specialist.
Sources: Holmberg et al., JNCI 2008 (HABITS); von Schoultz and Rutqvist, JNCI 2005, and Fahlén et al., Eur J Cancer 2013 (Stockholm); Kenemans et al., Lancet Oncol 2009 (LIBERATE).

Does your type of breast cancer or treatment change the answer?

Not for systemic HRT, but tamoxifen and aromatase inhibitors change the advice on vaginal oestrogen (see below). Even after receptor-negative cancer, no guideline supports routine systemic HRT, and the BMS notes it may not be risk-free.

If you carry a BRCA variant without breast cancer, NICE NG241 says to offer HRT until about 51 if your ovaries are removed before then.

Is vaginal estrogen safe after breast cancer?

It may be. Vaginal oestrogen comes as tablets, creams or a ring, and very little is absorbed. NICE NG23 suggests:

  • Moisturisers at least twice a week, and lubricants for sex (BMS).
  • If these do not help, vaginal oestrogen may be considered with your breast team, though its effect on recurrence is unknown and the evidence is sparse.
  • After oestrogen receptor-negative cancer it is likely to be safe. If you take tamoxifen, it would reduce any effect on recurrence.
  • If you take an aromatase inhibitor, vaginal oestrogen may make it work less well. Experts differ: NICE asks your specialists to plan together, the BMS generally advises against it, and ACOG allows a low dose if you and your oncologist agree. Please do not stop or change any cancer medicine without talking to your oncologist.

Studies of 8,461 Danish and 49,237 UK women were reassuring overall, but the Danish one found more recurrences alongside an aromatase inhibitor.

Can you take HRT after womb, ovarian or cervical cancer?

A gynaecological cancer does not automatically rule out HRT, says UK guidance (BGCS and BMS 2024).

After early womb (endometrial) cancer, a Cochrane review found no sign of significant harm in the only randomised trial (GOG 137), though it closed early.

Cervical, vaginal and vulval cancers are not considered hormone dependent, though after cervical adenocarcinoma the decision is more individual.

HRT after cancer at a glance

What guidance says about HRT tablets, patches or gels, and about vaginal oestrogen, for each type of cancer.
CancerHRT tablets, patches or gelsVaginal oestrogen
Breast Generally not recommended Only in exceptional cases of severe symptoms, after discussing the risks Case by case May be considered with your breast team; extra care on an aromatase inhibitor
Womb, low or intermediate risk Often possible Can be discussed Often possible Usually safe
Womb, higher risk Case by case Receptor-negative: case by case. Receptor-positive: not recommended Case by case Case by case
Uterine sarcoma Generally not recommended Avoid Generally not recommended Avoid
Ovarian, high-grade serous Often possible Not usually ruled out; discuss Often possible Usually safe
Ovarian, low-grade serous Case by case Stage I: discuss. Later stages: not recommended Often possible Usually safe; ask your team
Ovarian, granulosa cell Generally not recommended Usually avoided; stage I: specialist advice Often possible Usually safe
Cervical, vaginal, vulval Often possible Not ruled out Often possible Usually safe
Blood cancers Often possible Menopause before 40: advised, tailored with your haematologist Case by case Little evidence
Bowel, lung, melanoma, thyroid Case by case Lung: uncertain. Others: not ruled out; limited evidence Case by case Little evidence
Your oncologist or breast team will plan this with you. Please do not stop or change any cancer medicine without talking to them.
Sources: NICE NG101 and NG23; British Menopause Society 2025, BGCS and BMS 2024; ESHRE 2024; Fiol et al, 2023; British Thyroid Foundation.

Early menopause after chemotherapy, surgery or radiotherapy

Chemotherapy can stop your ovaries working whatever cancer you had, and womb cancer surgery usually brings on menopause if you have not been through it.

If menopause comes before 40 after a cancer that is not hormone sensitive, NICE advises HRT or the combined pill until about 51, agreed with your oncologist. This does not apply after any breast cancer, even a receptor-negative one.

Without hormones, menopause before 40 is linked with weaker bones and, on average, shorter lives, mainly from heart disease (ESHRE 2024; see why oestrogen matters). If you cannot take hormones, please ask what else protects your bones and heart.

Non-hormonal treatments for hot flushes and night sweats

If you cannot take HRT after breast cancer, trials show several other treatments can help (The Menopause Society). Paroxetine and fluoxetine are avoided with tamoxifen as they may weaken it, but please ask your doctor before stopping either. NICE advises against soy (isoflavone) supplements, red clover, black cohosh and vitamin E after breast cancer.

Non-hormonal treatments: what the trials found

If you cannot take HRT after breast cancer, several other treatments eased hot flushes in trials. Please check every option with your specialists.

Treatment

Placebo or usual care

Menopause CBT
After breast cancer (MENOS 1)
1.67
lower hot flush problem rating than usual care, on a 1 to 10 scale, at 9 weeks
Check with your specialists
Eases bother more than frequency
Venlafaxine
75 mg, breast cancer survivors
Fall in hot flush score at 4 weeks
Venlafaxine: 61%
Placebo: 27%
Check with your specialists
Suitable with tarmoxifen
Gabapentin
900 mg daily, women with breast cancer
Fall in hot flush score at 8 weeks
Gabapentin: 46%
Placebo: 15%
Check with your specialists
Can cause dependence
Oxybutynin
Women, two-thirds on tamoxifen or an aromatase inhibitor
Bigger fall in hot flushes than placebo
Check with your specialists
Dry mouth; long-term use may affect mernory in older women
Fezolinetant
Menopause trials
Fall in hot flushes at 12 weeks
Fezolinetant: 63%
Placebo: 40%
Check with your specialists
Liver tests; not during breast cancer treatment, including tamoxifen or an aromatase inhibitor
Elinzanetant
On tamoxifen or an aromatase inhibitor (OASIS-4)
Fewer hot flushes a day at 12 weeks
Elinzanetant: 7.8 fewer
Placebo: 4.2 fewer
Check with your specialists
UK licence covers this group; liver test first, not with ribociclib
Paroxetine and fluoxetine are avoided with tamoxifen as they may weaken it, but please ask your doctor before stopping either.
Sources: Mann et al., Lancet Oncol 2012 (MENOS 1); Loprinzi et al., Lancet 2000; Pandya et al., Lancet 2005; Leon-Ferre et al., JNCI Cancer Spectr 2020, EMA, Venza EPAR; Cardoso et al., N Engl J Med 2025 (OASIS-4)

What is different about menopause care after cancer in Dubai and the rest of the UAE?

In the UAE, menopause often overlaps with breast cancer treatment. Breast cancer is the most common cancer in UAE women (31.4% of their cancers in 2024) and is diagnosed most often at 40 to 49 (UAE cancer registry). Please check your insurance, and ask whether fezolinetant or elinzanetant is available here.

When should you see a specialist?

Please see a menopause specialist if:

  • Hot flushes, poor sleep or vaginal symptoms affect your daily life.
  • Your periods stopped before 45 after treatment.
  • Your treatment may bring on menopause. NICE advises talking to a menopause expert before and after treatment.

What to bring: your cancer type, stage and receptor status, current medicines, your oncologist’s latest letter and our questions to ask your doctor about HRT.

How Menovivre supports women after cancer

Dr Nirusha Kumaran leads the menopause clinic at Menovivre, where we offer menopause care after breast cancer or another cancer in Dubai. Options include non-hormonal medicines, local treatments for vaginal and urinary problems chosen to suit your medical history, and a bone health assessment such as our Postmenopausal Health Check. After breast cancer, please agree each treatment with your oncologist or breast team.

Frequently Asked Questions

Q1: Can I take HRT after breast cancer?

A: Usually not. NICE advises against routinely offering HRT tablets, patches or gels after breast cancer, except in exceptional cases after discussing the risks. Non-hormonal treatments come first, and your breast team can guide you.

Q2. Is vaginal estrogen safe after breast cancer?

A: It may be, if your breast team agrees. NICE says vaginal oestrogen can be considered when moisturisers are not enough and is likely to be safe after receptor-negative cancer. One study found more recurrences alongside an aromatase inhibitor.

Q3. What helps hot flushes after cancer?

A: CBT, venlafaxine, gabapentin, oxybutynin and elinzanetant eased hot flushes in trials. Paroxetine and fluoxetine are avoided with tamoxifen, but please ask your doctor before stopping either. Your menopause specialist can help you choose.
Dr. Nirusha Kumaran.

Dr. Nirusha Kumaran

Physician – Consultant – Family Medicine
Specialist in Functional and Longevity Medicine. Expert in Hormones optimisation and personalised precision medicine. Advanced Training in Bioidentical Hormone therapies, Peptide therapies and Nutrigenomics. Member of British Menopause society and British college of Functional Medicine.

Care Designed Around You.

The Menovivre newsletter brings expert-led insights across women’s health, empowering you with knowledge, personalised perspectives, and the reassurance that you’re not navigating this alone.